A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet regimen (pembrolizumab, trastuzumab, and doublet chemotherapy) as first-line therapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) (NCT029...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Choong-kun, Rha, Sun Young, Kim, Hyo Song, Jung, Minkyu, Kang, Beodeul, Che, Jingmin, Kwon, Woo Sun, Park, Sejung, Bae, Woo Kyun, Koo, Dong-Hoe, Shin, Su-Jin, Kim, Hyunki, Jeung, Hei-Cheul, Zang, Dae Young, Lee, Sang Kil, Nam, Chung Mo, Chung, Hyun Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556512/
https://www.ncbi.nlm.nih.gov/pubmed/36224176
http://dx.doi.org/10.1038/s41467-022-33267-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556512/
https://www.ncbi.nlm.nih.gov/pubmed/36224176
http://dx.doi.org/10.1038/s41467-022-33267-z

Ejemplares similares